The Stony Brook University Calm-Mom Study

July 28, 2023 updated by: Brittain Lynn Mahaffey, Stony Brook University

An Internet-Delivered Mind-Body Program for Reducing Prenatal Maternal Stress

The present trial will evaluate the feasibility, acceptability and preliminary efficacy of 2 different internet-delivered programs for prenatal maternal stress. The Stress Managment and Resiliency Training Program (SMART-Mom program), an 8-session Cognitive Behavior Therapy (CBT) based mind body program and the Mama Support Program, an 8-session social support group program. Sixty pregnant women (<20 weeks Estimated Gestational Age) will be screened and either enrolled in the online SMART Mom Program or the Mama Support Program. Outcomes, including maternal perceived stress, depression, and anxiety will be assessed at post-treatment, three, and six months post program completion. Potential impact on infant health outcomes will be assessed via post-delivery electronic medical record review.

Study Overview

Detailed Description

Aim 1: The investigators will conduct a randomized clinical trial (RCT; n=60) to assess the feasibility, acceptability and preliminary efficacy of the Stress Management and Resillency Training program (SMART Pregnancy) delivered online versus a time and attention matched prenatal support group (Mama Support). It is expected that SMART-pregnancy participants will demonstrate high levels of treatment engagement and adherence. It is predicted that participants in the SMART-Pregnancy condition will demonstrate improvements in emotional distress and stress regulation (as indexed by hair cortisol concentrations) at post-treatment and 3 month follow-up. Aim 2: The investigators will conduct a postnatal chart review to explore secondary treatment benefits including pre-and postnatal maternal health and birth outcomes.

Study Type

Interventional

Enrollment (Actual)

79

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

    • New York
      • Stony Brook, New York, United States, 11794
        • Stony Brook University, Department of Psychiatry

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • <21 weeks pregnant with medically confirmed viability
  • Speak, read and write in English fluently,
  • Endorse elevated levels of prenatal maternal stress (PNMS; i.e., New Prenatal Distress Questionnaire Score > 19).

Exclusion Criteria:

  • Current enrollment in individual or group psychotherapy
  • Current un-managed serious mental illness including bipolar disorder and psychosis
  • History of previous suicide attempt
  • Inappropriate for participation in group therapy format as determined by study director

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Intervention
Participants (n = 30) will be randomized to receive the SMART Pregnancy stress management program via an online portal.
SMART Pregnancy is an 8-session online stress management program offered in a group format. SMART Pregnancy is an adaptation of the Stress Management and Resiliency Training Program (Park et al., 2012).
Active Comparator: Treatment as usual
Participants (n = 30) will be randomized to receive treatment as usual, including referrals to community based support groups and individual mental health providers.
Participants will be enrolled in an 8-week time and attention matched, process-based support group.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in perceived stress as indexed by Perceived Stress Scale (PSS) score
Time Frame: baseline, 8 weeks post enrollment, 20 weeks post enrollment
Gold standard measure of subjective stress experiences. Total scores range from 0 to 40; higher scores indicate greater stress.
baseline, 8 weeks post enrollment, 20 weeks post enrollment
Change in prenatal maternal distress as indexed by Prenatal Distress Questionnaire (NuPDQ) score
Time Frame: baseline, 8 weeks post enrollment
Measure of prenatal maternal distress. Total scores range form 0-35; higher scores indicate greater pregnancy-related distress.
baseline, 8 weeks post enrollment

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Patient-Reported Outcomes Measurement Information System (PROMIS) V.1 Emotional Distress-Depression
Time Frame: baseline, 8 weeks post enrollment, 20 weeks post enrollment
Standardized depression symptom measure. Total scores range from 8-40; higher values represent greater distress/depression.
baseline, 8 weeks post enrollment, 20 weeks post enrollment
Patient-Reported Outcomes Measurement Information System (PROMIS) V.1 Emotional Distress-Anxiety
Time Frame: baseline, 8 weeks post enrollment, 20 weeks post enrollment
Standardized anxiety symptom measure. Total scores range from 6-30; higher values represent greater anxiety.
baseline, 8 weeks post enrollment, 20 weeks post enrollment
Cognitive and Affective Mindfulness Scale-Revised (CAMS-R)
Time Frame: baseline, 8 weeks post enrollment, 20 weeks post enrollment
Widely used mindfulness measure; total scores range from 12-60; higher scores represent greater mindfulness.
baseline, 8 weeks post enrollment, 20 weeks post enrollment
Measure of Current Status-Form A (MOCS-A)
Time Frame: baseline, 8 weeks post enrollment, 20 weeks post enrollment
Measure of stress-related coping. Total scores range from 0-52; higher scores represent better coping.
baseline, 8 weeks post enrollment, 20 weeks post enrollment

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Birthweight
Time Frame: Chart review occurring at 6 week postpartum visit.
Infant weight (in grams) at birth.
Chart review occurring at 6 week postpartum visit.
Gestational Age
Time Frame: Chart review occurring at 6 week postpartum visit.
Infant gestational age (in weeks) at birth.
Chart review occurring at 6 week postpartum visit.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Brittain L Mahaffey, PhD, Stony Brook University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

April 1, 2021

Primary Completion (Actual)

June 1, 2023

Study Completion (Actual)

June 1, 2023

Study Registration Dates

First Submitted

July 9, 2019

First Submitted That Met QC Criteria

July 11, 2019

First Posted (Actual)

July 12, 2019

Study Record Updates

Last Update Posted (Actual)

August 1, 2023

Last Update Submitted That Met QC Criteria

July 28, 2023

Last Verified

July 1, 2023

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 972565-4
  • K23HD092888 (U.S. NIH Grant/Contract)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

The investigators are committed to sharing the research data that is generated in this proposal. Research data will be shared according to NIH guidelines. All research data is collected and stored in accordance with HIPAA compliance, and any shared datasets resulting from human participant research will be free of any identifiers that would allow disclosure of individual subjects.

IPD Sharing Time Frame

Timelines for distribution of data will vary, however the study team will make every effort to make data available in a timely fashion. It is expected that data from this proposal will presented at scientific meetings, and publications will be made available through PubMed Central no later than 12 months after publication.

IPD Sharing Access Criteria

The data will be available to users under a data sharing agreement that includes a commitment to: 1) using the data for research purposes only, 2) properly securing the data in accordance with HIPAA compliance requirements, and 3) destroying the data after analyses are completed.

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • SAP

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Stress, Psychological

Clinical Trials on SMART Mom

3
Subscribe